Biography
Education
Institution | Degree | Dept or School | End Date |
---|---|---|---|
New York University, NY | M.B.A. | Business Administration | 2014 |
Stanford University | Resident | Dermatology | 2010 |
University of California, San Francisco | Research Fellowship | Derm-Oncology | 2010 |
The Brooklyn Hospital Center, NY | Internship | Medicine | 2006 |
Stanford University | Postdoctoral Fellowship | Epithelial Biology | 2005 |
AKH Vienna | Research Resident | Dermatology | 2001 |
University of Vienna | Research Fellow | Dermatology | 1999 |
Rappersberger, University of Vienna | PhD | Biology | 1998 |
University of Vienna | M.D. | School of Medicine | 1998 |
Board Certifications
- American Board of Dermatology
Clinical Expertise
Basal Cell Carcinoma
Squamous Cell Carcinoma
Skin Cancer in Immunosuppressed Patients
Melanoma
Merkel Cell Carcinoma
Kaposi's sarcoma
Skin adnexal tumors
Skin sarcomas
General Dermatology
Cutaneous Oncology
Program Affiliations
Department of Dermatology
UCSF Melanoma Center
Member, UCSF Helen Diller Family Comprehensive Cancer Center
Research Narrative
My research interest is centered in the mechanisms involved in cancer progression. In recent studies we studied the role of tumor-stroma interactions in epithelial tumorigenesis. Our goal now is to identify the earliest melanoma precursors and to study the mechanisms of intraepidermal melanoma progression taking advantage of a human tissue model of human melanoma.
Our laboratory is currently pursuing studies of the signaling and gene regulatory networks that control this process. Our studies are designed to identify potential biomarkers in unresected occult melanoma, establish improved methods to identify occult intraepidermal melanoma, rationalize resection margins, and find treatments to reduce melanoma recurrence at the primary site. My lab is also interested in the epigenetic mechanisms involved in cancer progression and in expression analysis between consecutive stages of tumor progression. These studies are designed to identify targets for genes involved in the migration, proliferation, and invasion of mutant melanocytes.
Research Interests
Xenograft models of cutaneous neoplasia
Mechanisms of cancer progression: signal transduction pathways
Molecular therapeutics in cancer
Epigenetics
Publications
- Poor melanoma outcomes and survival in Asian American and Pacific Islander patients.| | View in PubMed
- A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600E/K mutant advanced melanoma.| | View in PubMed
- MEK/CDK4,6 co-targeting is effective in a subset of NRAS, BRAF and 'wild type' melanomas.| | View in PubMed
- The lincRNA MIRAT binds to IQGAP1 and modulates the MAPK pathway in NRAS mutant melanoma.| | View in PubMed
- Cutaneous CD56+ T-cell lymphoma developing during pembrolizumab treatment for metastatic melanoma.| | View in PubMed
- Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma.| | View in PubMed
- New insights in melanoma biomarkers: long-noncoding RNAs.| | View in PubMed
- Pharmacological inhibitors of c-KIT block mutant c-KIT mediated migration of melanocytes and melanoma cells in vitro and in vivo.| | View in PubMed
- Phosphoproteomic Analyses of NRAS(G12) and NRAS(Q61) Mutant Melanocytes Reveal Increased CK2α Kinase Levels in NRAS(Q61) Mutant Cells.| | View in PubMed
- Oncogenic KIT mutations in different exons lead to specific changes in melanocyte phospho-proteome.| | View in PubMed
- Searching for the Chokehold of NRAS Mutant Melanoma.| | View in PubMed
- Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells.| | View in PubMed
- The burden of malignant melanoma--lessons to be learned from Austria.| | View in PubMed
- Time-Dependent Measurement of Adverse Events-Reply.| | View in PubMed
- Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression.| | View in PubMed
- Melanoma risk perception and prevention behavior among African-Americans: the minority melanoma paradox.| | View in PubMed
- Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma.| | View in PubMed
- Correction: Cost-Effectiveness Of Treatment Strategies for BRAF-Mutated Metastatic Melanoma.| | View in PubMed
- The risk of melanoma in pilots and cabin crew: UV measurements in flying airplanes.| | View in PubMed
- The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial.| | View in PubMed
- Detection of GNAQ mutations and reduction of cell viability in uveal melanoma cells with functionalized gold nanoparticles.| | View in PubMed
- Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer.| | View in PubMed
- The risk of melanoma in airline pilots and cabin crew: a meta-analysis.| | View in PubMed
- Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.| | View in PubMed
- Mutant NRASQ61 shares signaling similarities across various cancer types--potential implications for future therapies.| | View in PubMed
- Cost-effectiveness of treatment strategies for BRAF-mutated metastatic melanoma.| | View in PubMed
- Merkel cell carcinoma: mitoses, expression of Ki-67 and bcl-2 correlate with disease progression.| | View in PubMed
- DNA and aptamer stabilized gold nanoparticles for targeted delivery of anticancer therapeutics.| | View in PubMed
- Single-point mutation detection in RNA extracts using gold nanoparticles modified with hydrophobic molecular beacon-like structures.| | View in PubMed
- Melanoma immunotherapy.| | View in PubMed
- Mycoplasma pneumoniae-associated mucositis--case report and systematic review of literature.| | View in PubMed
- Low-dose inhalation of interleukin-2 bio-chemotherapy for the treatment of pulmonary metastases in melanoma patients.| | View in PubMed
- NRAS mutant melanoma--undrugable?| | View in PubMed
- Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.| | View in PubMed
- Cutting edge in medical management of cutaneous oncology.| | View in PubMed
- Modeling inducible human tissue neoplasia identifies an extracellular matrix interaction network involved in cancer progression.| | View in PubMed
- A laminin-collagen complex drives human epidermal carcinogenesis through phosphoinositol-3-kinase activation.| | View in PubMed
- Type VII collagen is required for Ras-driven human epidermal tumorigenesis.| | View in PubMed
- [Erythema induratum-nodular vasculitis].| | View in PubMed
- Carbamazepine-induced DRESS syndrome with recurrent fever and exanthema.| | View in PubMed
- The plant lectin wheat germ agglutinin inhibits the binding of pemphigus foliaceus autoantibodies to desmoglein 1 in a majority of patients and prevents pathomechanisms of pemphigus foliaceus in vitro and in vivo.| | View in PubMed
- Sustainable correction of junctional epidermolysis bullosa via transposon-mediated nonviral gene transfer.| | View in PubMed
- PhiC31 integrase-mediated nonviral genetic correction of junctional epidermolysis bullosa.| | View in PubMed
- [New immunosuppressive agents for treating psoriasis].| | View in PubMed
- Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue.| | View in PubMed
- Stable nonviral genetic correction of inherited human skin disease.| | View in PubMed
- Pathogenesis of the permeability barrier abnormality in epidermolytic hyperkeratosis.| | View in PubMed
- A localized variant of paraneoplastic pemphigus: acantholysis associated with malignant melanoma.| | View in PubMed